Feliza Mirasol is the science editor for BioPharm International.
Celltrion Gains Expanded Indication Approval from FDA for its Actemra Biosimilar for CRS Therapy
August 9th 2025The additional approval expands the label for Avtozma (tocilizumab-anoh) to now include the treatment of cytokine release syndrome, which aligns the therapy with all indications for which Actemra is approved in the US.
FDA Accepts Breyanzi sBLA from Bristol Myers Squibb and Grants It Priority Review for MZL
August 6th 2025Bristol Myers Squibb is seeking approval of Breyanzi (lisocabtagene maraleucel) to treat relapsed or refractory marginal zone lymphoma, making this the fifth cancer type for which the cell therapy would be approved.